American Society for Investigative Pathology, November 2013, Vol 5, No. 3

Have you recently completed any milestones in YOUR training or career? 

On behalf of the Committee for Career Development, Women and Minorities, we would like to invite you to submit your recent accomplishments to be featured in the ASIP Trainee Newsletter.

This “Trainee Milestones and Updates” page highlights honors/awards, grants/ fellowships, new jobs/promotions and publications of ASIP Trainee members, whether you're just beginning your academic career, or you're well on your way as a seasoned young investigator!

To submit an article or announcement for the next issue of the ASIP Trainee Newsletter, please email your article to asiptrainees@gmail.com. Submissions are subject to review. Please include a digital photograph with your submission. 

ASIP Trainee Newsletter
Co-Editors
Kari Nejak-Bowen 
Cindy Thomas-Charles

Advisors
Jayne Reuben
Mark E. Sobel
Monte S. Willis

Trainee Milestones and Updates

 

William Puszyk, PhD

Department of Pathology, Immunology, and Laboratory Medicine

University of Florida

Publications:

Gestational diabetes impairs Nrf2-mediated adaptive antioxidant defenses and redox signaling in fetal endothelial cells in utero.

Cheng X, Chapple SJ, Patel B, Puszyk W, Sugden D, Yin X, Mayr M, Siow RC, Mann GE. Diabetes. 2013 Sep 5. [Epub ahead of print]
PMID:23974919

Linking metabolism and epigenetic regulation in development of hepatocellular carcinoma.
Puszyk WM, Trinh TL, Chapple SJ, Liu C.
Lab Invest. 2013 Sep;93(9):983-90. doi: 10.1038/labinvest.2013.94. Epub 2013 Aug 5.
PMID:23917878

The epigenetic regulator PLZF represses L1 retrotransposition in germ and progenitor cells.
Puszyk W, Down T, Grimwade D, Chomienne C, Oakey RJ, Solomon E, Guidez F.
EMBO J. 2013 Jul 3;32(13):1941-52. doi: 10.1038/emboj.2013.118. Epub 2013 May 31.
PMID:23727884

Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma.
Ogunwobi OO, Puszyk W, Dong HJ, Liu C.
PLoS One. 2013 May 28;8(5):e63765. doi: 10.1371/journal.pone.0063765. Print 2013.
PMID:23723997

OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma.
Zhao X, Tian C, Puszyk WM, Ogunwobi OO, Cao M, Wang T, Cabrera R, Nelson DR, Liu C.
Lab Invest. 2013 Jan;93(1):8-19. doi: 10.1038/labinvest.2012.144. Epub 2012 Oct 29.
PMID:23108376

 


 

Andrei Turtoi, PhD

Laboratory of Metastasis Research

University of Liege

Publications:

Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies.

Turtoi A, Blomme A, Debois D, Somja J, Delvaux D, Patsos G, Di Valentin E, Peulen O, Mutijima EN, De Pauw E, Delvenne P, Detry O, Castronovo V. Hepatology. 2013 Jul 6. doi: 10.1002/hep.26608. [Epub ahead of print] PMID: 23832580 [PubMed - as supplied by publisher]

"At the University of Liege, I am taking part in translational cancer research with focus on discovery of novel proteins for targeted therapies. We have specific interest in understanding why today’s targeted therapies fail in the heterogeneous tumor environment. Recently we have published a study where we have characterized the proteomic heterogeneity in colorectal cancer liver metastasis. We have surprisingly found a pattern of antigen expression that can now be used to more effectively organize targeted therapy approaches in patients."

Myoferlin is a key regulator of EGFR activity in breast cancer.

Turtoi A, Blomme A, Bellahcène A, Gilles C, Hennequière V, Peixoto P, Bianchi E, Noel A, De Pauw E, Lifrange E, Delvenne P, Castronovo V. Cancer Res. 2013 Sep 1;73(17):5438-48. doi: 10.1158/0008-5472.CAN-13-1142. Epub 2013 Jul 17. PMID: 23864327 [PubMed - in process]

"We have also recently discovered and patented a new tumor-enriched membrane protein, called myoferlin, which has the potential to be used as novel, effective therapeutic target in several different cancers (breast, pancreas, colon etc.). We have been recently able to shed light on the fully unknown role of this protein in cancer. Namely, myoferlin is a key factor that controls the function of EGFR, participating in the proper internalization and degradation of the receptor. Considering the therapeutic significance of EGFR targeting, our findings identify myoferlin as an novel candidate function to target for future drug development."